Trastuzumab (Anti-HER2) is a recombinant humanized monoclonal antibody targeting HER2 antigen, which is overexpressed in invasive breast cancers. Trastuzumab has been used for the research of HER2 positive Metastatic Breast and Gastric Cancer.
Trastuzumab-SAP is a bonded toxin between a biotinylated recombinant humanized antibody to HER2 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Trastuzumab-SAP eliminates cells expressing human HER2. All other cells are left untouched.
Trastuzumab-SAP is available individually (Cat. #IT-95) or as a kit (Cat. #KIT-95) which includes Trastuzumab-SAP and BIgG-SAP Human (Cat. #IT-77)
keywords: trastuzumab, HER2, breast cancer, metastatic, gastric, immunotoxin, streptavidin, saporin
Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: The most attractive application of nanobodies
Abdolvahab MH, Karimi P, Mohajeri N, Abedini M, Zare H (2024) Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: The most attractive application of nanobodies. Cancer Cell Int 24(1):67. doi: 10.1186/s12935-024-03259-8 PMID: 38341580
Objective: Using nanobodies to deliver saporin to breast cancer cells.
Summary: Through the binding of saporin to a nanobody, a fragment of an antibody, breast cancer cells that over-express Her2 can be targeted and eliminated. Binding of saporin in nanoparticles to 11A4 nanobody (anti-HER2 receptor) showed dose-dependent cytotoxicity against SK-BR-3 cells when tested. Photochemical internalization of saporin loaded nanoparticles also demonstrated dose-dependent cytotoxicty in SK-BR-3 breast cancer cells.
Related Products: Trastuzumab (Anti-HER2)-SAP (Cat. #BETA-038)
See Also:
browse all references for this product | back to top
